Ascendis Pharma (ASND) Stock Statistics & Valuation Metrics

Ascendis Pharma has a market cap or net worth of $9.91B. The enterprise value is $8.94B.

Ascendis Pharma has 60,970,566 shares outstanding. The number of shares has decreased by -2.65% in one year.

Ascendis Pharma’s return on equity (ROE) is 3.58 and return on invested capital (ROIC) is -37.00%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Ascendis Pharma had revenue of 363.64M and earned -378.08M in profits. Earnings per share was -6.53.

In the last 12 months, operating cash flow was -41.13M and capital expenditures -715.00K, giving a free cash flow of -41.85M billion.

Ascendis Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Ascendis Pharma upcoming earnings date is Sep 9, 2025, TBA (Confirmed).

Ascendis Pharma as a current ratio of 1.17, with Debt / Equity ratio of -446.39%

In the past 12 months, Ascendis Pharma has paid 4.84M in taxes.

Ascendis Pharma EV to EBITDA ratio is -27.56, with an EV/FCF ratio of -25.99.

Ascendis Pharma has $517.92M in cash and marketable securities with €847.27M in debt, giving a net cash position of $329.35M billion.

Gross margin is 85.30%, with operating margin of -76.66%, and net profit margin of -103.97%.

The average price target for Ascendis Pharma is $231.86, which is 11.43% higher than the current price. The consensus rating is Strong Buy